Abstract
Objective
To determine the prognostic value of FDG-PET after surgical resection in patients with ovarian carcinoma, we compared the results of FDG-PET and serum CA-125 level and prognosis of patients.Methods: Eighteen patients underwent a total of 32 FDG-PET examinations following surgery for ovarian carcinoma from October 2001 to December 2002 at our hospital (median follow-up period, 31 months). Age of the patients at the time of the initial FDG-PET examination ranged from 31 to 73 years (mean 52 years) and the period from surgery to the initial FDG-PET examination ranged from 5 to 109 months (mean 30 months). Serum CA-125 levels were determined on the occasion of each FDG-PET examination. Recurrent tumors were treated with surgery in 5 cases, radiotherapy in 2 cases, and chemotherapy in 9 cases.
Results
The initial FDG-PET examinations revealed that 13 cases had positive and 5 cases had negative findings, which included 2 false positive cases. The survival rate for all patients at 1 year and 2 years after the initial examination was 82% and 63%, respectively. Two-year survival rates in patients with positive and negative FDG-PET findings were 51% and 83%, respectively, and the difference was not statistically significant (p = 0.19). Furthermore, 4 patients with normal CA-125 levels and 14 patients with elevated CA-125 levels showed 2-year survival rates of 100% and 51%, respectively, and they were not significantly different (p = 0.11). For all 32 examinations, the 2-year survival rates for patients with normal CA-125 levels (100%) were significantly higher (p = 0.025) than that for patients with elevated CA-125 levels (47%), however there was no significant difference (p = 0.20) between FDG-PET positive cases (53%) and negative cases (83%).
Conclusion
The prognosis of patients with positive FDG-PET findings was less favorable than that of patients with negative findings. However, over the mean extended observation period of about 2.5 years, no significant difference in the prognosis of patients was observed between the two groups. The results of the present study indicate that elevated serum CA-125 levels may be more useful for evaluating the prognosis of ovarian cancer during the post-operative follow-up than FDG-PET findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.Eur Radiol 2000; 10:761–767.
Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.Anticancer Res 2001; 21:3691–3694.
Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.AJR Am J Roentgenol 2001; 176:1449–1454.
Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose.Eur J Nucl Med Mol Imaging 2002; 29:797–803.
Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.Gynecol Oncol 2001; 83:310–315.
Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. [18F] FDG PET as a substitute for second-look lapa-rotomy in patients with advanced ovarian carcinoma.Eur J Nucl Med Mol Imaging 2004; 31:196–201.
Rustin G, Tuxen M. Use of CA-125 in follow-up of ovarian cancer.Lancet 1996; 20; 348:191–192.
Zanaboni F, Presti M, Scarfone G, Bolis G. CA-125 reliability in predicting ovarian cancer recurrence.Tumori 1989; 75:69–71.
Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?J Clin Oncol 2004; 22:4051–4058.
Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA-125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?Gynecol Oncol 1993; 49:3–7.
Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, et al. Serum CA-125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study.Int J Gynecol Cancer 1997; 7:78–83.
Khan N, Oriuchi N, Yoshizaki A, Kanuma T, Higuchi T, Endo K. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.Ann Nucl Med 2005; 19:137–145.
Hogberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer.Acta Oncol 2001; 40:340–360.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okazaki, A., Tamaki, T., Uki, A. et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 20, 171–174 (2006). https://doi.org/10.1007/BF03027426
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03027426